After a brain injury, cells that normally nourish nerves may actually kill them instead, a new study in rodents finds. This 'reactive' phenomenon may be the driving factor behind neurodegenerative diseases like glaucoma, a leading cause of blindness.
In 2003, Heiko Braak proposed that Parkinson's disease is caused by a pathogen in the gut that could pass through the intestinal mucosal barrier and spread to the brain through the nervous system. Until now, no evidence of a specific pathogen that may trigger PD was found; now researchers report for the first time a significant overabundance of a cluster of opportunistic pathogens in the PD gut.
AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology
Older men who have a weak or irregular circadian rhythm guiding their daily cycles of rest and activity are more likely to later develop Parkinson's disease, according to a new study by scientists at the UC San Francisco Weill Institute for Neurosciences who analyzed 11 years of data for nearly 3,000 independently living older men.
Pathological protein clumps are characteristic of a series of diseases, such as Alzheimer's disease, Parkinson's disease, and type 2 diabetes. Scientists at Forschungszentrum Jülich, Heinrich Heine University Düsseldorf, and Maastricht University have now used cryo-electron microscopy to obtain a sharp image for the first time of how individual molecules are arranged in protein strings, which constitute the deposits typical for diabetes. The structure of the fibrils is very similar to that of Alzheimer's fibrils.
EPFL researchers, in collaboration with UTSW and UCSD scientists, have developed a computational protein design approach, and used it to obtain the first ever high-resolution structure of an activated dopamine receptor in its natural cell membrane environment. The breakthrough will open up a new dimension in drug discovery for Parkinson's disease and perhaps other disorders.
Rice University neuroengineers have created a tiny surgical implant that can electrically stimulate the brain and nervous system without using a battery or wired power supply.
The contributions of researchers from The University of Texas at El Paso have yielded the first indication that carbon quantum dots, a class of nanoparticles, can be utilized to combat neurological disorders, according to a paper published in the journal Processes as part its special issue on protein biosynthesis and drug design and delivery.
Growth factors such as glial cell line-derived neurotrophic factor (GDNF) were initially thought to be exciting new treatments for Parkinson's disease (PD), but trials have been disappointing. A panel of prominent leaders in the field convened to discuss whether there is a future for this approach and what any future PD trial involving GDNF and other GDNF family neurotrophic factors should consider. Their discussions and recommendations are published in the Journal of Parkinson's Disease.
Researchers have uncovered a link between the structure of the protein alpha-synuclein and its likelihood to misfold and aggregate.